Fresenius Wins Over Skeptics as Kabi Momentum Reshapes the Investment Case

Fresenius lifts 2026 EPS guidance, Kabi shines with biosimilars, and Helios concerns ease, driving shares up 15% in 30 sessions.

The German healthcare group has spent much of the past two years fighting a defensive battle with investors, but the tide appears to be turning. A flurry of target-price upgrades, a ratings agency endorsement and a sharply improved earnings outlook have combined to give Fresenius its most convincing bull narrative in years — and the market is listening. The stock has climbed 15 percent over the past 30 sessions, closing at 47.07 euros.

Guidance Upgrade Sparks Analyst Stampede

The catalyst came on August 4, when Fresenius lifted its full-year forecast for 2026. Management now expects currency-adjusted growth in core earnings per share of 10 to 15 percent, a meaningful step up from the previous guidance range of 5 to 10 percent. The revision was underpinned by robust operational momentum across both Kabi and Helios, the group's two principal divisions.

The numbers released three days later did little to temper enthusiasm. Second-quarter group revenue rose 6 percent organically to 5.864 billion euros, while currency-adjusted EBIT before special items climbed 10 percent to 719 million euros. For Kabi — the infusion, biosimilar and clinical nutrition arm — management sharpened its margin guidance, now projecting a 2026 EBIT margin at the upper end of the 16.5 to 17.0 percent band.

The market response was swift. The DZ Bank lifted its fair value to 58 euros on August 10 with a "Buy" rating, while Morgan Stanley raised its target from 49 to 52 euros the same day, maintaining an "Overweight" stance. UBS followed on August 12, with analyst Graham Doyle bumping his price objective from 54 to 56 euros and keeping a "Buy" recommendation.

Kabi Takes Centre Stage

Doyle's thesis hinges on a simple observation: Kabi has become the group's primary profit engine, and no other division currently contributes more to earnings. He frames the second quarter as a potential inflection point for the company, with the segment's biopharmaceutical pipeline adding a fresh layer of growth optionality.

Regulatory developments support that view. On August 7, Kabi announced FDA approval of a Rituximab biosimilar for the US market. In parallel, the agency and its European counterpart accepted filing applications for a Vedolizumab biosimilar candidate — a sign that the division's pipeline is maturing beyond its legacy infusion franchise.

There is, however, a wrinkle. Fresenius Kabi initiated a US recall of one batch of Tyenne (Tocilizumab-aazg) in the 400-mg/20-mL vial format due to the risk of glass particles. The recall is limited in scope but serves as a reminder that biosimilar manufacturing carries inherent quality-control challenges.

Helios Overhang Lifts

The hospital operator Helios had been a persistent source of investor anxiety, weighing on the share price through much of the year. Management appears to have addressed those concerns during the latest earnings call, with Doyle noting that worries around the clinic business have been largely dispelled. That removes a significant overhang that had capped the stock's upside.

The group is also preparing a structural change: a conversion from bearer shares to registered shares, designed to facilitate more direct communication with shareholders. The move is procedural rather than strategic, but it signals a broader effort to improve investor relations.

Rating Agency Adds Its Voice

Fitch, for its part, confirmed Fresenius's credit rating at "BBB-" but revised its outlook from "stable" to "positive" — a shift that arrived just days before the UBS note. The agency cited the sharpened corporate profile under the #FutureFresenius strategy and improved credit metrics. Net financial debt to EBITDA stands at 2.6x, at the lower end of the group's 2.5x to 3.0x target corridor, underscoring the balance-sheet discipline that underpins the improved assessment.

A Broader Recovery Story

The positive read-through extends beyond the parent company. Fresenius Medical Care, in which the group holds roughly 32 percent, saw its earnings growth accelerate to 23 percent in the second quarter, and the dialysis specialist appointed Cassie McLean as its new board member for care delivery.

With a market capitalisation of around 26.5 billion euros, Fresenius now finds itself in the unusual position of having operational progress, improving creditworthiness and analyst consensus all pointing in the same direction. The combination of Kabi's commercial strength, the easing of Helios-related concerns and a more favourable ratings backdrop gives the equity story a coherence it has lacked for some time — and suggests the valuation debate may shift from whether the turnaround is real to how far it can run.